Los Angeles Capital Management LLC Lowers Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Los Angeles Capital Management LLC lowered its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 5.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 405,971 shares of the biopharmaceutical company’s stock after selling 25,575 shares during the period. Los Angeles Capital Management LLC owned about 0.07% of Royalty Pharma worth $11,404,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in RPRX. Allworth Financial LP increased its position in Royalty Pharma by 89.8% during the 3rd quarter. Allworth Financial LP now owns 953 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 451 shares during the period. Beck Bode LLC raised its stake in Royalty Pharma by 0.6% in the fourth quarter. Beck Bode LLC now owns 73,042 shares of the biopharmaceutical company’s stock worth $2,052,000 after buying an additional 464 shares in the last quarter. Toroso Investments LLC lifted its stake in shares of Royalty Pharma by 0.9% during the 3rd quarter. Toroso Investments LLC now owns 57,102 shares of the biopharmaceutical company’s stock worth $1,550,000 after purchasing an additional 504 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Royalty Pharma by 112.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,005 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 531 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its stake in Royalty Pharma by 10.8% in the third quarter. PNC Financial Services Group Inc. now owns 5,509 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 536 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on RPRX. Bank of America decreased their target price on shares of Royalty Pharma from $40.00 to $38.00 and set a “buy” rating for the company in a research report on Friday, April 12th. The Goldman Sachs Group dropped their target price on Royalty Pharma from $56.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, February 20th. JPMorgan Chase & Co. dropped their price target on Royalty Pharma from $45.00 to $42.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 20th. Finally, StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, April 11th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $46.75.

Royalty Pharma Stock Down 1.2 %

Royalty Pharma stock opened at $28.41 on Friday. Royalty Pharma plc has a fifty-two week low of $25.92 and a fifty-two week high of $35.70. The company has a market cap of $16.97 billion, a PE ratio of 15.03 and a beta of 0.47. The company has a debt-to-equity ratio of 0.61, a quick ratio of 7.90 and a current ratio of 7.90. The business’s 50-day simple moving average is $29.36 and its two-hundred day simple moving average is $28.58.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.12. The company had revenue of $736.00 million during the quarter, compared to analyst estimates of $702.90 million. Royalty Pharma had a net margin of 48.22% and a return on equity of 26.93%. Equities analysts anticipate that Royalty Pharma plc will post 3.95 EPS for the current year.

Royalty Pharma Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 17th will be given a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a yield of 2.96%. The ex-dividend date of this dividend is Thursday, May 16th. Royalty Pharma’s dividend payout ratio is currently 44.44%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.